Eli Lilly shares hold above $1,117 support as technicals point to potential rebound: weekly analysis

Traders Union
All News
Stocks
Eli lilly slips 1.77% this week

Highlights

Shares of Eli Lilly declined 1.77% this week to $1,127 and are trading below key short-term moving averages.
Technical indicators are oversold and suggest limited downside, but momentum remains negative with downward pressure persisting.
The expected range for next week is $1,082 to $1,189, with support at $1,117 and resistance at $1,151.

FDA approvals and investor inflows bolster sentiment amid new product launches

LLY received two new FDA approvals for its diabetes treatments, with Simply Wall St News reporting Mounjaro (tirzepatide) and telpotetide both gaining new cardiovascular indications for adults with type 2 diabetes. The launch of LillyDirect, a telehealth platform allowing direct-to-consumer sales of drugs like Zepbound, was highlighted by PharmExec. Additionally, several institutional investors, including Saudi Central Bank and Empirical Finance LLC, have increased or initiated new holdings in LLY during the second quarter, as shown in SEC filings covered by MarketBeat and The Markets Daily.

Consolidation dominates as oversold readings battle persistent bearish momentum

The daily chart signals a contained move within a narrow range, with volatility for the past week at 2.99%. Both the CCI at -119.02 and the Stochastic RSI at 0.43 are oversold, indicating the potential for a short-term rebound, but persistent negative readings from MACD and the Awesome Oscillator suggest continued downside pressure. Immediate support is seen at $1,117, with resistance at $1,151 and the Ichimoku Kijun at $1,200 acting as a higher resistance level. This setup points to further consolidation, but oversold conditions could limit additional losses in the near term.

Downside risks remain elevated unless support holds in the week ahead

Next week, the expected range is $1,082 to $1,189, with a 36% probability of an increase and a 64% probability of a decrease. The base case calls for continued consolidation between support at $1,117 and resistance at $1,151. A move above $1,151 would increase the risk of a rebound toward $1,189, while a drop below $1,117 would open the door for a deeper pullback toward $1,082.

Jainam Mehta, market strategist, sees shares of Eli Lilly trading near $1,127 after a 2% decline this week, with daily indicators suggesting oversold conditions but still showing downside pressure. He notes that strong news flow — including two fresh FDA approvals for new cardiovascular indications in diabetes treatments and increased institutional holdings — has not yet offset recent technical weakness. Mehta believes a further consolidation between support at $1,117 and resistance at $1,151 is likely, with oversold readings hinting at limited downside if support holds. "For the coming week, I’ll watch for a contrarian entry if buyers show up near $1,117, but caution is warranted until momentum decisively shifts."

Earlier, analysts noted that Eli Lilly's stock showed relative resilience despite sector-wide drug trial setbacks, supported by optimism around its broader pipeline and obesity franchise. The current technical setup underscores ongoing consolidation, with investors advised to watch support at $1,117 and resistance at $1,151 as key levels that could define the next directional move.

Source of Data: LLY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.